Skip to main content

TIDEWATER

tidewaternews-logo
SUBSCRIBE
Menu
Menu
tidewaternews-logo
Subscribe
Menu

Archives

AI Is Deciding Which B2B Brands Get Considered Before Buyers Ever Visit a Website

AI Is Deciding Which B2B Brands Get Considered Before Buyers Ever Visit a Website

B2B buyer behavior is changing in a way most companies haven’t fully accounted for. The early stages of vendor discovery, once driven by search engines, referrals, and analyst reports—are increasingly happening inside AI systems. Tools like ChatGPT and Perplexity are no longer just assisting research. They are actively shaping which vendors are considered in the first place. That shift moves the point of influence earlier in the buying process, and outside the traditional channels companies know how to optimize. Historically, B2B buyers built shortlists before engaging with vendors. Research has consistently shown that most purchasing decisions are heavily influenced before a sales conversation ever begins. What’s different now is that AI systems are increasingly participating in that process, filtering options and presenting a narrowed set of recommendations before a human evaluates them. In practical terms, this means fewer opportunities to enter consideration later. If a company is not included in the initial set of options generated by an AI system, it may never be evaluated at all. At the same time, visibility in AI systems does not map cleanly to traditional search performance. A brand can rank highly on Google, have strong domain authority, and still be absent from AI-generated answers. The reason often has little to do with brand strength and more to do with how content is structured and delivered. Many AI crawlers do not process JavaScript in the same way traditional search engines do. Websites that rely heavily on client-side rendering may appear complete to users and search engines, while presenting little or no readable content to AI systems. In these cases, a site that appears fully optimized can be effectively invisible to the tools shaping early-stage buyer research. Even when content is accessible, another layer of complexity emerges: fragmentation. Different AI platforms draw from different source pools, apply different weighting to those sources, and generate responses using different internal logic. As a result, the same query can produce entirely different vendor recommendations depending on the system used. Data across multiple studies suggests that overlap between major AI platforms is minimal. A company that appears consistently in one system may be absent in another. This makes the idea of a single “AI optimization strategy” increasingly difficult to sustain. The implication is that visibility is no longer a single-channel problem. It is a multi-system challenge, where presence must be earned across different environments that do not fully align with each other. That shift is also changing how companies compete. AI-generated answers tend to present a limited number of options, often just a handful of vendors. This compresses the competitive landscape before a buyer has the chance to explore alternatives. In crowded markets, where differentiation is already difficult, this narrowing effect can determine which companies are considered and which are excluded entirely. The result is a growing gap between companies that are consistently surfaced by AI systems and those that are not, regardless of their underlying capabilities. For many organizations, the most difficult part of this transition is that its impact is not immediately visible in standard analytics. AI-driven interactions are often untracked. A buyer may consult an AI system, receive a recommendation, and later visit a company’s website directly or through a branded search. The influence of the AI system is real, but it does not appear clearly in attribution models. This creates a blind spot in how performance is measured. Traffic may appear to come from direct or organic channels, while the decision-making process that led to that visit remains hidden. As a result, companies may underestimate the role AI systems are already playing in their pipeline. Addressing this shift requires a different approach to visibility, one that goes beyond rankings and on-site optimization. It involves ensuring that content is machine-readable, that key questions are answered with clarity and specificity, and that the brand is represented consistently across third-party sources that AI systems rely on for validation. Companies like Resonate Labs are beginning to focus specifically on this emerging layer of visibility, helping organizations understand how they are represented across AI platforms and where gaps exist. As AI continues to move upstream in the buying process, the question is no longer just whether buyers can find a brand. It is whether the systems guiding those buyers can find —and recognize— it at all.

Scania signs agreement for new biogas buses in intercity operations

Transport operator Nobina will introduce 27 new Scania biogas buses into service on behalf of public transport authority Skånetrafiken. With low noise levels and low emissions, the vehicles underline the parties’ continued commitment to sustainable public transport.SÖDERTÄLJE, Sweden,…

Ericsson appoints David Hammarwall Head of Business Area Networks

Effective as of October 1, 2026Becomes member of Ericsson’s Executive Team, reporting to the CEOSTOCKHOLM, June 18, 2026 /PRNewswire/ — Ericsson (NASDAQ: ERIC) today announces the appointment of David Hammarwall as its new Head of Business Area Networks…

California Medicaid Funding Dispute Raises Questions About Federal Oversight

California Medicaid Funding Dispute Raises Questions About Federal Oversight

The Trump administration’s decision to withhold approximately $1.3 billion in Medicaid reimbursements from California over alleged fraud concerns is emerging as one of the most consequential federal-state healthcare disputes in recent years. Beyond the immediate financial impact, the move is raising questions about the future balance of power between Washington and state Medicaid agencies, the role of fraud enforcement in public healthcare programs, and the stability of funding relied upon by providers serving millions of low-income Americans. According to Jim Maguire, co-founder of GMS, the decision represents a significant departure from the traditional relationship between federal and state Medicaid administrators. Historically, federal oversight has largely operated on a post-payment basis, with audits and retroactive reviews leading to clawbacks after funds have already been distributed. “This action changes that dynamic by withholding reimbursement up front, materially constraining the state’s cash flow and increasing federal leverage at the front end,” Maguire said. If sustained, he believes the approach could fundamentally alter incentives for states by placing much greater emphasis on payment integrity before federal dollars are released. While critics have characterized the dispute as politically motivated, Maguire argues that fraud prevention remains the central issue. “Medicaid fraud is real, it is costly, and it diverts precious resources away from people who genuinely need care and cannot afford it otherwise,” he said. Although he acknowledges that the administration’s anti-fraud posture carries political dimensions, he does not view politics as the primary driver. Instead, he sees the action as part of a broader effort to strengthen accountability in a program that serves more than 70 million Americans. “If fraud is widespread, then the response to it should be equally broad, aggressive in blue states, aggressive in red states, and consistent wherever abuse is found,” he added. The scale of the reimbursement freeze has attracted particular attention. Maguire describes the move as unprecedented and believes it should serve as a warning to Medicaid programs nationwide. “The scale of this action is unprecedented, and it should get the attention of every state Medicaid program in the country,” he said. He hopes the dispute encourages regulators, managed care organizations, and providers to intensify efforts to identify and eliminate fraud before more punitive federal interventions become necessary. In his view, program integrity and payment integrity can no longer be treated as secondary administrative functions but must become central components of Medicaid management. For other states with large Medicaid populations, the California dispute may establish a powerful precedent. Maguire argues that states should view the episode as both a warning and an opportunity to strengthen oversight mechanisms. “Program integrity, payment transparency, and managed care oversight can no longer be treated as secondary administrative functions,” he said. The message, he suggests, is clear: states that fail to demonstrate robust controls over Medicaid spending may face heightened scrutiny and potentially greater federal intervention in the future. Despite the headline figure, Maguire believes California possesses the financial capacity to absorb a temporary reimbursement delay. With more than $92 billion in federal Medicaid funding received during fiscal 2024, the withheld amount represents roughly 1.4% of the state’s annual federal Medicaid support. “In practical terms, California should still be able to continue funding Medicaid, paying providers, and managing the shortfall while it works to reconcile and recover the withheld funds,” he said. However, he cautions that financial resilience at the state level does not necessarily translate to stability for every provider within the healthcare ecosystem. Rural hospitals, hospice operators, and smaller home healthcare agencies could face disproportionate risks if enforcement actions result in delayed payments or prolonged audits. “Rural hospitals and smaller organizations could face serious cash-flow issues,” Maguire warned. He argues that federal and state officials must carefully calibrate enforcement efforts to avoid unintended consequences. “If claims are pended, payments are delayed, and providers are subjected to prolonged or overly burdensome audits, the downstream effects will be significant.” Weakening financially stable providers in pursuit of fraud prevention, he noted, could create new challenges for patient access and healthcare delivery. Looking ahead, Maguire expects the California dispute to be part of a broader trend rather than an isolated event. “Yes, I believe it is reasonable to expect more aggressive Medicaid oversight across the country over the next few years,” he said. Whether driven by fraud concerns, fiscal pressures, or evolving federal priorities, the administration’s actions may mark the beginning of a new era in Medicaid enforcement—one in which states face heightened scrutiny, providers encounter greater compliance demands, and the debate over balancing accountability with access becomes increasingly central to healthcare policy nationwide.